Evidence map›Paper›PMID 32328901›Full record

ReviewJournal of nephrology2020

Atherogenic dyslipidemia and diabetic nephropathy.

Giuseppina Russo, Pamela Piscitelli, Annalisa Giandalia, Francesca Viazzi, Roberto Pontremoli, Paola Fioretto, Salvatore De Cosmo

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 4 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Current perspectives on lipid management in diabetic kidney disease: Can fibrates offer advantages over statins for renal outcomes?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Giuseppina RussoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Pamela PiscitelliUnit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo Della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo, FG, Italy.
Annalisa GiandaliaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Francesca ViazziUniversity of Genova and Ospedale Policlinico San Martino-IST, Genoa, Italy.
Roberto PontremoliUniversity of Genova and Ospedale Policlinico San Martino-IST, Genoa, Italy.
Paola FiorettoDepartment of Medicine, University of Padova, Padova, Italy.
Salvatore De CosmoUnit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo Della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo, FG, Italy. s.decosmo@operapadrepio.it.
Ospedale Policlinico San Martino · ITUniversity of Messina · ITCasa Sollievo della Sofferenza · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease is associated with altered lipid metabolism and lipid accumulation. Although it is though that hyperlipemia is a consequence of kidney dysfunction, several lines of evidence support that hyperlipidemia may contribute to the onset and progression of kidney disease, also in diabetes. This review describes the results of recent observational studies supporting the concept that glucose is only partly responsible for kidney damage onset, while a cluster of factors, including hypertriglyceridemia and low HDL-cholesterol, could play a relevant role in inducing onset and progression of DKD. We also report the results of randomized clinical trials investigating in type 2 diabetic patients the role of drug improvement of hypertriglyceridemia on renal outcomes. Finally, we discuss putative mechanisms linking hyperlipidemia (i.e. hypertriglyceridemia or low HDL cholesterol) with kidney disease.

Indexed as

AtherosclerosisDiabetes Mellitus, Type 2Diabetic NephropathiesDyslipidemiasCholesterol, HDLHumansKidneyTriglyceridesCholesterol, HDLTriglyceridesAtherogenic dyslipidemiaDiabetic kidney diseaseHDL-CTriglycerides

Identifiers

PMID32328901
OpenAlexW3017618483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.